Business Wire

CYCLIC-MATERIALS

16.7.2024 15:01:29 CEST | Business Wire | Press release

Share
Microsoft Makes Strategic Investment in Cyclic Materials to Accelerate Climate Tech Innovation

Cyclic Materials, an advanced metals recycling company building a circular supply chain for rare earth elements and other critical metals, today announced it has received an equity investment from Microsoft’s Climate Innovation Fund, an initiative dedicated to accelerating technology development and deployment of new climate innovations. This investment is representative of Microsoft’s commitment to a circular economy and interest in hard drive rare earth element recycling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716818494/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Over the past two years, Cyclic has developed a patent-pending technology, CC360TM, to specifically address the challenge of recovering rare earths contained in end-of-life hard drives. While hard drives are typically sent to an IT asset disposal (ITAD) company at the end of life, this disposal process is designed for data destruction, followed by shredding of drives for the recovery of other metals such as gold and silver. The rare earths contained are currently not recovered. With the CC360TM, ITAD companies can separate a portion of hard drives for rare earth recovery, while retaining the rest of the hard drives for their traditional process. These separated magnets can then be processed by Cyclic Materials’ processing technologies, unlocking an additional value stream from hard drive disposal.

“Microsoft is working to achieve zero waste across our direct operations, products, and packaging by 2030. This means adopting a circular economy approach,” said Brandon Middaugh, Senior Director, Climate Innovation Fund, Microsoft. “As demand for rare earth elements continues to grow in importance, we’re excited to support the creation of a sustainable supply of these materials with this investment.”

Established in 2021, Cyclic Materials is an industry leader developing technologies that are capable of economically, sustainably and domestically transforming end-of-life (EOL) products into valuable raw materials. The recycling of rare earths delivers significant environmental benefits in comparison to mining processes, including a reduced carbon footprint and water usage. Cyclic Materials recently opened its Kingston-based “Hub100” plant, deploying its proprietary hydrometallurgical technology, REEPure and helping fulfill the ever-increasing demand for domestic sources of mixed rare earth oxide (MREO) in North America.

“We have been working with Cyclic over the past few months to trial the use of the CC360 TM in our operations. We have seen tremendous performance improvements through the development and achieved throughput of one hard drive per second,” said Sean Magann, chief commercial officer at Sims Lifecycle Services (SLS). “This solution enables us to drive further value out of disposed hard drives, by reclaiming the critical rare earths, while maintaining the data security of the hard drives being disposed. An additional benefit is the reduction of magnets clogging our shredders. We look forward to deploying this technology across our operations.”

“We’re thrilled by this endorsement from Microsoft’s Climate Innovation Fund as a key strategic investor who is like minded in creating a circular supply chain for rare earth elements contained in hard drives used in their data center operations,” said Ahmad Ghahreman, co-founder and CEO of Cyclic Materials. “This support enables us to accelerate the deployment of our commercial facilities, which is a critical step in growing the domestic supply of rare earths in North America that support the energy transition. Additionally, we value the input that SLS has provided, helping us to validate our new CC360TM technology that we believe will prove invaluable to large data center operators such as Microsoft as they work towards their circularity and sustainability goals.”

To learn more about Cyclic Materials, please visit www.cyclicmaterials.earth.

About Cyclic Materials

Established in 2021, Cyclic Materials is a cleantech company creating a circular supply chain for rare earth elements and other materials critical to supporting the energy transition. Through its innovative technology, the company economically, sustainably and domestically transforms end-of-life products into valuable raw materials that are essential to the production of electric vehicles, wind turbines and motors for the electronics we use in our daily lives. In 2024, Cyclic opened its Hub100 plant in Kingston, Ontario – the first facility to produce recycled Mixed Rare Earth Oxide (rMREO) in North America using its proprietary hydrometallurgical technology, REEPure™. With the global market for magnet rare earth elements forecasted to increase dramatically by 2030, establishing new sources of these critical elements is vital to support the electrification of the economy across the globe. Cyclic plans to scale its technology in North America, Europe and Asia. To learn more, visit cyclicmaterials.earth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716818494/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye